NASDAQ$FOLD
Amicus Therapeutics Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Announced third quarter 2021 financial results and corporate updates.
Amicus Therapeutics announced its Q3 2021 financial results, featuring an 18% increase in total Galafold revenue compared to Q3 2020. The company is on track to complete the business combination of its gene therapy business with ARYA IV, resulting in the launch of Caritas Therapeutics.
- Total Galafold revenue reached $79.5 million, marking an 18% increase compared to Q3 2020.
- The company is reiterating its 2021 revenue guidance of $300 million to $315 million.
- The FDA accepted the AT-GAA BLA and NDA for Pompe disease for review, and marketing authorization applications were submitted to the European Medicines Agency.
- Amicus is on track to complete the planned business combination of its gene therapy business with ARYA IV, leading to the launch of Caritas Therapeutics in late 2021 or early 2022.
Headline financials
Revenue & EPS history
Amicus Therapeutics · Revenue · Quarterly
$79.5M
Revenue by segment
Amicus Therapeutics · $79.5M total across 1 segment · Q3 2021
- Galafold$79.5M+18.0%100.0%
Forward guidance
Amicus Therapeutics is reiterating its 2021 revenue guidance of $300M-$315M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
-0.3%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+1.3%
Avg return
30 days after
39%
25 / 64 earnings
Positive
+28.4%
Q3 2016
Best reaction
-16.1%
Q2 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +0.2% | +0.0% | +0.6% | |
| Q3 2025 | +1.6% | +0.1% | +12.3% | |
| Q2 2025 | -2.5% | +14.0% | +23.8% | |
| Q1 2025 | -13.0% | -19.4% | -21.0% | |
| Q4 2024 | -2.9% | -5.2% | -8.5% | |
| Q3 2024 | -6.5% | -8.9% | -17.1% | |
| Q2 2024 | +14.8% | +17.2% | +16.5% | |
| Q1 2024 | -9.0% | -8.0% | -0.9% | |
| Q4 2023 | -7.4% | -2.8% | -14.9% | |
| Q3 2023 | -14.8% | -12.3% | -4.2% | |
| Q2 2023 | +9.1% | +7.0% | -1.4% | |
| Q1 2023 | -4.2% | -8.1% | +5.1% | |
| Q4 2022 | -3.9% | -8.1% | -15.9% | |
| Q3 2022 | +6.5% | +11.1% | +20.5% | |
| Q2 2022 | +17.5% | +19.2% | +10.5% | |
| Q1 2022 | +7.5% | +19.5% | +40.0% | |
| Q4 2021 | +0.0% | -0.5% | +13.2% | |
| Q3 2021 | -3.8% | -4.9% | -12.6% | |
| Q2 2021 | +8.5% | +7.6% | +20.1% | |
| Q1 2021 | -1.5% | -2.7% | +8.5% | |
| Q4 2020 | -9.0% | -14.7% | -19.5% | |
| Q3 2020 | -1.3% | +7.5% | +11.8% | |
| Q2 2020 | -5.3% | -6.6% | -9.5% | |
| Q1 2020 | -1.6% | +2.5% | +8.7% | |
| Q4 2019 | -4.2% | -0.6% | -7.2% | |
| Q3 2019 | +3.2% | +7.0% | +5.8% | |
| Q2 2019 | -8.5% | -12.0% | -21.9% | |
| Q1 2019 | -4.8% | -11.7% | -13.2% | |
| Q4 2018 | +12.0% | +9.1% | +9.4% | |
| Q3 2018 | -6.0% | -10.6% | -16.3% | |
| Q2 2018 | +4.7% | +5.4% | -16.8% | |
| Q1 2018 | -4.7% | -4.0% | +11.2% | |
| Q4 2017 | -6.2% | -9.0% | -0.7% | |
| Q3 2017 | -10.4% | -8.5% | -6.6% | |
| Q2 2017 | +1.1% | -8.9% | +6.3% | |
| Q1 2017 | +1.2% | +8.4% | +27.3% | |
| Q4 2016 | +14.5% | +18.5% | +9.9% | |
| Q3 2016 | +28.4% | +49.8% | -4.6% | |
| Q2 2016 | -9.5% | +0.0% | +1.4% | |
| Q1 2016 | -9.6% | — | — | |
| Q4 2015 | -4.3% | — | — | |
| Q3 2015 | +8.9% | — | — | |
| Q2 2015 | -16.1% | — | — | |
| Q1 2015 | -1.5% | — | — | |
| Q4 2014 | -0.5% | — | — | |
| Q3 2014 | -0.5% | — | — | |
| Q2 2014 | -2.8% | — | — | |
| Q1 2014 | +0.5% | — | — | |
| Q4 2013 | +2.8% | — | — | |
| Q3 2013 | +3.9% | — | — | |
| Q2 2013 | +7.8% | — | — | |
| Q1 2013 | -1.3% | — | — | |
| Q4 2012 | +11.0% | — | — | |
| Q3 2012 | -13.3% | — | — | |
| Q2 2012 | -5.5% | — | — | |
| Q1 2012 | +6.4% | — | — | |
| Q4 2011 | -4.9% | — | — | |
| Q3 2011 | +3.9% | — | — | |
| Q2 2011 | +6.7% | — | — | |
| Q1 2011 | -1.1% | — | — | |
| Q4 2010 | -4.4% | — | — | |
| Q3 2010 | -2.5% | — | — | |
| Q2 2010 | +10.0% | — | — | |
| Q1 2010 | -1.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro